APArchitha Menon P.

Architha Menon P.

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Architha Menon P. has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Dhanapala N.

    Department of Otorhinolaryngology, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India

    1 shared publication
  • Garima Singh

    Cell Cycle and Cancer Laboratory, School of Biotechnology, Institute of Science, Banaras Hindu University, Varanasi, India

    1 shared publication
  • Hemalatha B R

    Shri Atal Bihari Vajpayee Medical College & Research Institute, Bangalore, Karnataka, India

    1 shared publication
  • Manasa P.

    Department of Otorhinolaryngology, Shri Atal Bihari Vajpayee Medical College and Research Institute, Bangalore, Karnataka, India

    1 shared publication
  • Pruthvi Raj S

    Shri Atal Bihari Vajpayee Medical College & Research Institute, Bangalore, Karnataka, India

    1 shared publication
  • Pruthvi Raj S.

    Kempegowda Institute of Medical Sciences , Bengaluru

    1 shared publication

Latest Publications

  • Open Access

    Post Covid-19 Mandibular Mucormycosis: A Rare and Deviant Site of Presentation

    by Ravishankar C, Hemalatha B R, Pruthvi Raj S, Architha Menon P, Garima Singh

    Introduction:Mandibular involvement in mucormycosis is rare, and only a few cases of post covid-19 mandibular mucormycosis have been reported to date. Materials & methods: This is a retrospective descriptive case series study conducted at a tertiary care centre.We report the clinico-epidemiological profile and management of 5 cases of post covid mandibular mucormycosis. All patients received intravenous antifungals at the earliest and underwent surgical debridement of the infected bone. Results: 4 patients were managed satisfactorily. 1 patient succumbed to the disease. Extent of debridement was based on the clinical, radiological and intraoperative assessment of the mandible. Conclusion: Mandibular mucormycosis is rare and early recognition of symptoms and treatment is imperative in reducing the spread of disease, decreasing the extent of resection and postoperative reconstruction.

  • Open Access

    Orbital involvement in COVID-19 associated mucormycosis

    by Manasa P., Dhanapala N., Pruthvi Raj S., Architha Menon P., Rahul Gopi, Theerta V. M., Shwetha Kumari C.

    Background: Mucormycosis is an opportunistic, potentially lethal, fungal infection predisposed by uncontrolled diabetes mellitus, immunosuppressive therapy, primary or secondary immunodeficiency, injudicious use of corticosteroids, hematological malignancies, hematological stem cell transplantation, solid organ malignancies, solid organ transplantation. Rhino-orbital mucormycosis is the commonest form of mucormycosis. This study was done to discuss the management strategies (orbital decompression/clearance, orbital exenteration, retrobulbar amphotericin B) in the treatment of orbital mucormycosis and its clinical outcomes. Methods: A retrospective descriptive study was conducted between May 2021 and October 2021 at Bowring and Lady Curzon hospital, Shri Atal Bihari Vajpayee Medical College and Research Institute, Karnataka, India. 181 patients with post-COVID RTPCR negative rhino-orbital mucormycosis were included in the study. Patients underwent endoscopic orbital clearance, orbital exenteration based on the extent of orbital involvement. Results: 143 were males and 38 were females. 160 patients underwent orbital decompression and clearance of necrotic tissue. 21 patients underwent orbital exenteration. Final visual acuity of perception of light (PL) positive and above was achieved in 147 patients. 57/58 (98.27%) patients had improvement in extraocular movements post-surgery and resolution of diplopia after orbital decompression/clearance. Conclusions: Endoscopic orbital clearance helps to reduce the need for orbital exenteration in PL negative patients. TRAmB as adjuvant helps in decreasing the ocular morbidity. Orbital exenteration is best avoided, when possible, to avoid cosmetic disfigurement and psychological trauma to the patient.